Monogenetic Disorders Testing MarketSize, Share & Industry Analysis, 2026-2034By Test TypeBy Disease TypeBy End-userBy TechnologyBy Product & Service
Full title & scope — all 5 axes with their segments
Monogenetic Disorders Testing Market Size, Share & Industry Analysis, By Test Type (Diagnostic Testing, Prenatal Testing, Carrier Testing, New-Born Screening, Predictive and Pre-Symptomatic Testing), By Disease Type (Thalassaemia, Sickle Cell Anemia, Cystic fibrosis, Familial Hypercholesterolemia, Huntington's Disease, Severe Combined Immunodeficiency, Polycystic Kidney Disorder, Neurofibromatosis, Gaucher's Disease, Tay-Sachs Disorder), By End-user (Hospitals, Specialized Clinics, Ambulatory Surgical Centers), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Sanger Sequencing, Microarray, Fluorescence In Situ Hybridization), By Product & Service (Reagents & Consumables, Instruments, Software & Services), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By Test TypeDiagnostic Testing · Prenatal Testing · Carrier Testing
- 02By Disease TypeThalassaemia · Sickle Cell Anemia · Cystic fibrosis
- 03By End-userHospitals · Specialized Clinics · Ambulatory Surgical Centers
- 04By TechnologyNext-Generation Sequencing · Polymerase Chain Reaction · Sanger Sequencing
- 05By Product & ServiceReagents & Consumables · Instruments · Software & Services
- 06By Region
Market Analysis & Outlook
Monogenetic disorders testing covers laboratory assays that detect single-gene mutations responsible for inherited conditions such as cystic fibrosis, sickle cell anemia and Tay-Sachs disorder, delivered through carrier screening, diagnostic confirmation, newborn panels, predictive testing and prenatal analysis. Testing is performed on blood, saliva or amniotic samples using PCR, next-generation sequencing, Sanger sequencing, microarray or FISH platforms. Buyers include hospital laboratories, specialized genetic clinics and ambulatory centers that order these assays on behalf of clinicians, expectant parents and at-risk families.
The global monogenetic disorders testing market is valued at USD 650 million in 2025 and is set to reach USD 1692.1 million by 2034, a compound annual growth rate of 11.37% across the 2026-2034 forecast period. The study tracks the market across USD 410 million in 2020, USD 592.8 million in 2024, USD 715 million in 2026 and USD 1098.4 million in 2030.
On the test type axis, growth rates run from 10.32% for New-Born Screening up to 13.93% for Prenatal Testing. Diagnostic Testing carries the volume: USD 207.9 million and 31.98% of revenue in 2025, USD 495.1 million and 29.26% in 2034. Share moves toward Prenatal Testing and Predictive and Pre-Symptomatic Testing and away from Diagnostic Testing, Carrier Testing and New-Born Screening, though no line shrinks in revenue terms.
Cut by disease type, the largest line is Thalassaemia: 18% of 2025 revenue, worth USD 117 million, and 16.5% at USD 279.2 million by 2034. Familial Hypercholesterolemia grows faster at 14.01% against 10.15%, moving from 12% of revenue to 15% by 2034. Both this axis and the test type one divide the same revenue, which is why they are alternative views rather than components.
USD 272.1 million of 2025 revenue is generated in North America, 41.86% of the global total and the largest regional share; it reaches USD 643 million by 2034. Europe is next at 25.93% and USD 168.5 million, and Middle East and Africa last at 3.86%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.
The 2025 total is triangulated from published sources and category proxies rather than an independently sourced count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five test type lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD MillionRevenue in USD Million. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 650 million in 2025 to USD 1692.1 million in 2034, a compound annual rate of 11.37%, having reached USD 592.8 million in 2024 from USD 410 million in 2020.
- Diagnostic Testing is the largest test type line at USD 207.9 million in 2025, a 31.98% share, reaching USD 495.1 million and 29.26% of revenue by 2034.
- At 13.93%, Prenatal Testing grows faster than any other test type line, moving from USD 156 million and 24% of revenue in 2025 to USD 500.5 million and 29.58% in 2034.
- Against a base case of USD 1692.1 million in 2034, the study also reports a bear case at USD 1539.8 million and a bull case at USD 1874.9 million, with the assumptions behind each set out separately.
- North America holds 41.86% of global revenue in 2025 at USD 272.1 million, the largest of the five regions tracked, and reaches USD 643 million by 2034.
- 87.98% of North America's base-year revenue comes from the United States alone: USD 239.4 million in 2025, rising to USD 559.4 million by 2034, which is why it is that region's worked example.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By by test type
Base year 2025Diagnostic Testing leads with 32.0% of by test type segment revenue.
Share of by test type segment revenue, most recent base year.
Three movements define the forecast period in the global monogenetic disorders testing market: how the test type mix changes, where regional weight shifts, and the rate at which the total compounds.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Prenatal Testing grows faster than New-Born Screening. Between 2026 and 2034, 13.93% growth in Prenatal Testing against 10.32% in New-Born Screening pulls the test type mix apart. Over the forecast period that moves Prenatal Testing from 24% of revenue to 29.58%, and New-Born Screening from 16% to 14.7%. The revenue figures behind that are USD 156 million to USD 500.5 million and USD 104 million to USD 248.8 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.
Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 22.5% of revenue in 2025 to 27% in 2034, worth USD 146.3 million rising to USD 456.9 million; Latin America moves from 5.86% of revenue in 2025 to 6.5% in 2034, worth USD 38.1 million rising to USD 110 million; Middle East and Africa moves from 3.86% of revenue in 2025 to 4.5% in 2034, worth USD 25 million rising to USD 76.1 million. The remaining regions grow in absolute terms while giving up share: North America at 41.86% moving to 38%, Europe at 25.93% moving to 24%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
Fifteen years without a discontinuity. The market moves through USD 410 million in 2020, USD 592.8 million in 2024, USD 650 million in 2025, USD 715 million in 2026, USD 1098.4 million in 2030 and USD 1692.1 million in 2034. No year breaks the trajectory, and the 11.37% forecast rate compares with 9.65% recorded over 2020-2025, a continuation rather than an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the test type and regional axes, not by the headline rate.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
Prenatal Testing compounds at 13.93% against 11.37% for the market, rising from USD 156 million in 2025 to USD 500.5 million in 2034 and from 24% of revenue to 29.58%. The market's overall 11.37% depends on that rate holding: at the 10.32% recorded by New-Born Screening, the same revenue base would compound to a materially smaller 2034 total. Where a supplier sits on this axis therefore decides whether it grows with the market or below it.
- 02North America carries 41.86% of the base and keeps growing
North America is the largest region at USD 272.1 million in 2025, 41.86% of global revenue, and reaches USD 643 million by 2034 while holding 38%. Europe adds a further 25.93% at USD 168.5 million, reaching USD 406.1 million. Between them they hold most of the base and most of the revenue added over the period, so equal-weighting the regions in a plan misstates where the growth is.
- 03A demonstrated trajectory, not a projected turnaround
USD 410 million in 2020, USD 592.8 million in 2024 and USD 650 million in 2025: 9.65% compound growth before the forecast period even begins. From there the forecast carries 11.37% through to USD 1692.1 million in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 11.37% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Rising global prevalence of inherited disorders and expanding newborn screening mandates | High | +350 | High | High | High |
| 2 | Falling per-test cost of next-generation sequencing broadening access | High | +300 | Medium | High | High |
| 3 | Wider adoption of carrier and prenatal screening within reproductive care pathways | Medium-High | +220 | Medium | Medium | High |
| 4 | Broadening insurance and public reimbursement coverage for genetic testing | Medium | +160 | Low | Medium | Medium |
| 5 | Deeper integration between diagnostic laboratories and specialized genetic clinics | Medium | +110 | Low | Low | Medium |
| 6 | Others | Low | +99.1 | Low | Low | Low |
| Total | +1239.1 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High out-of-pocket cost and limited reimbursement across lower-income markets | Medium | −95 | High | Medium | Medium |
| 2 | Shortage of trained genetic counselors constraining test ordering | Medium | −62 | Medium | Medium | Low |
| 3 | Ethical and psychological concerns limiting uptake of predictive and pre-symptomatic testing | Low | −40 | Medium | Low | Low |
| Total | −197 | |||||
Drivers contribute 1239.1 Million and restraints remove 197 Million, a net 1042.1 Million, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 11.37% into its parts and three show up: an already-large base compounding, the test type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Where the forecast could miss: reimbursement expansion for genetic testing stalls in emerging markets and the shortage of trained genetic counselors persists longer than assumed, slowing the conversion of eligible patients into tested patients across carrier, predictive and prenatal testing. That path reaches USD 1539.8 million by 2034 instead of USD 1692.1 million, off an unchanged USD 650 million in 2025.
- 02The largest line is not the fastest
Diagnostic Testing carries 31.98% of 2025 revenue at USD 207.9 million but compounds at 10.32% against 11.37% for the market, taking its share to 29.26% by 2034 even as revenue rises to USD 495.1 million. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
What would beat the forecast: sequencing cost declines faster than the base case and newborn screening mandates expand into additional jurisdictions sooner, pulling adoption of next-generation sequencing based panels forward across all five test types. That case reaches USD 1874.9 million in 2034 rather than USD 1692.1 million, and it is worth testing against a reader's own read of the market.
- 02Prenatal Testing is where share changes hands
Prenatal Testing grows at 13.93% against 11.37% for the market, adding revenue from USD 156 million in 2025 to USD 500.5 million in 2034 and taking its share from 24% to 29.58%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Diagnostic Testing.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
With 31.98% of 2025 revenue and 29.26% of 2034 revenue (USD 207.9 million rising to USD 495.1 million) Diagnostic Testing is where the market's exposure sits. Anything that changes demand for it changes the headline number; nothing else on the axis carries that weight.
- 02Single-country exposure in North America
87.98% of the leading region is one country: the United States, at USD 239.4 million against North America's USD 272.1 million in 2025, and USD 559.4 million by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesfive segmentation axes are reported; by test type, by disease type, end-user, technology and product & service. Every one of them divides the same revenue, which makes them views of one market from different commercial angles rather than components of it.
All five test type lines expand in revenue terms over the forecast period. Share is the dividing line; two take it, the others cede it.
By Test Type · 5 segments
Diagnostic Testing Led by Test type in 2025, with Prenatal Testing Growing Fastest
- Largest Diagnostic Testing · 32%
- Fastest Prenatal Testing · 13.9%
- Moves most Prenatal Testing · +5.6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Diagnostic Testing | $208M | 32% | $495M | 29.3%-2.7 | 10.3% |
| Prenatal Testing | $156M | 24% | $501M | 29.6%+5.6 | 13.9% |
| Carrier Testing | $130M | 20% | $311M | 18.4%-1.6 | 10.3% |
| New-Born Screening | $104M | 16% | $249M | 14.7%-1.3 | 10.3% |
| Predictive and Pre-Symptomatic Testing | $52M | 8% | $137M | 8.1%+0.1 | 11.4% |
Diagnostic testing leads because it confirms suspected disorders across the widest range of clinical presentations and is ordered by the broadest set of physicians. Prenatal testing is growing fastest as non-invasive sampling methods extend screening earlier into pregnancy and expectant parents increasingly request confirmation ahead of invasive procedures, while predictive and pre-symptomatic testing grows more slowly given its dependence on individual choice. Leadership changes hands: Prenatal Testing is the largest line by 2034, not Diagnostic Testing. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Disease Type · 10 segments
By Disease Type
- Largest Thalassaemia · 18%
- Fastest Familial Hypercholesterolemia · 14%
- Moves most Familial Hypercholesterolemia · +3 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Thalassaemia | $117M | 18% | $279M | 16.5%-1.5 | 10.2% |
| Sickle Cell Anemia | $104M | 16% | $254M | 15%-1 | 10.4% |
| Cystic fibrosis | $97.50M | 15% | $237M | 14%-1 | 10.4% |
| Familial Hypercholesterolemia | $78M | 12% | $254M | 15%+3 | 14% |
| Huntington's Disease | $58.50M | 9% | $152M | 9% | 11.2% |
| Severe Combined Immunodeficiency (SCID) | $52M | 8% | $135M | 8% | 11.2% |
| Polycystic Kidney Disorder | $52M | 8% | $144M | 8.5%+0.5 | 12% |
| Neurofibromatosis | $39M | 6% | $102M | 6% | 11.2% |
| Gaucher's Disease | $32.50M | 5% | $84.60M | 5% | 11.2% |
| Tay-Sachs Disorder | $19.50M | 3% | $50.80M | 3% | 11.2% |
2025 to 2034 revenue and share by line: Thalassaemia USD 117 million to USD 279.2 million (18% in 2025), Sickle Cell Anemia USD 104 million to USD 253.8 million (16% in 2025), Cystic fibrosis USD 97.5 million to USD 236.9 million (15% in 2025), Familial Hypercholesterolemia USD 78 million to USD 253.8 million (12% in 2025), Huntington's Disease USD 58.5 million to USD 152.3 million (9% in 2025), Severe Combined Immunodeficiency (SCID) USD 52 million to USD 135.4 million (8% in 2025), Polycystic Kidney Disorder USD 52 million to USD 143.8 million (8% in 2025), Neurofibromatosis USD 39 million to USD 101.5 million (6% in 2025), Gaucher's Disease USD 32.5 million to USD 84.6 million (5% in 2025), Tay-Sachs Disorder USD 19.5 million to USD 50.8 million (3% in 2025). Thalassaemia Led by Disease type in 2025, with Familial Hypercholesterolemia Growing Fastest Thalassaemia and sickle cell anemia lead because both carry established, mandated newborn screening programs in the regions where they are most prevalent, driving consistent testing volume. Familial hypercholesterolemia is growing fastest as cascade screening of relatives following an index diagnosis becomes standard cardiology practice, a pathway that did not exist at meaningful scale for most of the other listed conditions. Thalassaemia remains the largest line through 2034, so the axis changes in proportion rather than in order.
By End-user · 3 segments
Specialized Clinics Outpaces the Axis While Hospitals Holds the Largest Share
- Largest Hospitals · 52%
- Fastest Specialized Clinics · 12.6%
- Moves most Hospitals · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals | $338M | 52% | $812M | 48%-4 | 10.2% |
| Specialized Clinics | $221M | 34% | $643M | 38%+4 | 12.6% |
| Ambulatory Surgical Centers | $91M | 14% | $237M | 14% | 11.2% |
Hospitals lead because they house the laboratory infrastructure and specialist referral networks needed to order and interpret genetic tests at scale. Specialized clinics are growing fastest as dedicated genetic counseling practices expand independently of hospital systems, giving patients a direct route to carrier and predictive testing without a hospital referral. The order does not change: Hospitals is still largest in 2034, and what moves is how much it holds.
By Technology · 5 segments
Next-Generation Sequencing (NGS) Both Leads the Technology Axis and Grows Fastest on It
- Largest Next-Generation Sequencing (NGS) · 34%
- Fastest Next-Generation Sequencing (NGS) · 13.9%
- Moves most Next-Generation Sequencing (NGS) · +8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Next-Generation Sequencing (NGS) | $221M | 34% | $711M | 42%+8 | 13.9% |
| Polymerase Chain Reaction (PCR) | $169M | 26% | $372M | 22%-4 | 9.2% |
| Sanger Sequencing | $130M | 20% | $237M | 14%-6 | 6.9% |
| Microarray | $78M | 12% | $220M | 13%+1 | 12.2% |
| Fluorescence In Situ Hybridization (FISH) | $52M | 8% | $152M | 9%+1 | 12.7% |
Next-generation sequencing leads because it can test for many single-gene mutations in one run, replacing several narrower assays with one workflow. It is also the fastest-growing platform as declining sequencing cost makes it competitive with cheaper but narrower methods such as PCR and Sanger sequencing for an expanding share of test orders. Next-Generation Sequencing (NGS) remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Product & Service · 3 segments
Reagents & Consumables Led by Product & service in 2025, with Software & Services Growing Fastest
- Largest Reagents & Consumables · 58%
- Fastest Software & Services · 14.8%
- Moves most Software & Services · +6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Reagents & Consumables | $377M | 58% | $931M | 55%-3 | 10.6% |
| Instruments | $156M | 24% | $355M | 21%-3 | 9.6% |
| Software & Services | $117M | 18% | $406M | 24%+6 | 14.8% |
Reagents and consumables lead because every test performed consumes a fresh kit, making this line recur with testing volume rather than with one-time instrument placement. Software and services are growing fastest as laboratories increasingly pay for variant interpretation and reporting support rather than building that expertise in house. By 2034 Reagents & Consumables is still ahead, making this a shift in weight rather than a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3.9 points of share move elsewhere by 2034, while revenue still grows 2.4×.
- Rank 1 of 5
- 2025 share 41.9%
- By 2034 38%
- Revenue $272M → $643M
In North America, 41.86% of global revenue puts 2025 at USD 272.1 million rising to USD 643 million in 2034. Among the five regions it ranks first by revenue in both years.
38% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the test type split tracks the global one; 31.98% of 2025 revenue in Diagnostic Testing, fastest growth of 13.93% in Prenatal Testing. Revenue for North America is broken out by every segmentation axis and by country in the full report.
United States
Sets the pace for North America at 88% of it, growing 2.3×.
- In region 1 of 2
- Of region 88%
- Of global 36.8%
- Revenue $239M → $559M
The United States is the largest market within North America, generating USD 239.4 million in 2025 and projected to reach USD 559.4 million by 2034. Because it is 87.98% of the region in the base year, North America's totals move with this one country rather than with a spread of them. Regional revenue of USD 272.1 million in 2025 and USD 643 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The test type pattern in the United States is the global one: 31.98% of 2025 revenue in Diagnostic Testing, 29.26% by 2034, against 13.93% growth in Prenatal Testing taking it from 24% to 29.58%. Since 87.98% of North America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-test type revenue for the United States appears on its own in the full report.
Monogenetic disorder tests reach the U.S. market through two distinct routes, and a supplier's obligations depend on which one applies. A kit manufactured and sold to third-party laboratories is regulated by the Food and Drug Administration as an in vitro diagnostic device, requiring clearance, approval, or a risk-based classification decision before marketing, along with device labelling and quality system conformity. A test developed and run within a single laboratory is instead treated as a laboratory-developed test, overseen through the Clinical Laboratory Improvement Amendments program administered by the Centers for Medicare and Medicaid Services, which governs analytical validity and laboratory certification rather than premarket device review. Genetic counseling and result-reporting practices are shaped by professional guidance rather than a single binding federal standard.
The suppliers tracked in this study (Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings) compete in the United States across the test type lines above. Diagnostic Testing, at 31.98% of 2025 revenue, is where the volume sits, and Prenatal Testing, growing at 13.93%, is where position changes hands over the forecast period. Per-company positioning and share at country level are in the full report only.
Canada
2nd-largest in North America, growing 2.6×.
- In region 2 of 2
- Of region 12%
- Of global 5%
- Revenue $32.70M → $83.60M
Within North America, Canada accounts for 12.02% of regional revenue and 5.03% of the global total, worth USD 32.7 million in 2025 and USD 83.6 million by 2034.
Europe Market Analysis
The 2nd-largest region covered — 1.9 points of share move elsewhere by 2034, while revenue still grows 2.4×.
- Rank 2 of 5
- 2025 share 25.9%
- By 2034 24%
- Revenue $169M → $406M
USD 168.5 million of 2025 revenue is generated in Europe, 25.93% of the global monogenetic disorders testing market rising to USD 406.1 million in 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
24% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
Within the region the test type split tracks the global one; 31.98% of 2025 revenue in Diagnostic Testing, fastest growth of 13.93% in Prenatal Testing. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 2.3×.
- In region 1 of 3
- Of region 28%
- Of global 7.3%
- Revenue $47.20M → $110M
The largest single market in Europe is Germany, at USD 47.2 million in 2025 and USD 109.7 million in 2034. It accounts for 28.02% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 168.5 million and USD 406.1 million for the region, it is why this market rather than a smaller one is the one reported in full.
Germany buys along the same lines as the market globally; Diagnostic Testing first at 31.98% of 2025 revenue and 29.26% in 2034, Prenatal Testing fastest at 13.93% on a share moving from 24% to 29.58%. Its 28.02% weight in Europe means those movements carry straight into the regional totals. Revenue by test type for Germany is reported separately in the full report.
As an European Union member state, Germany applies the EU In Vitro Diagnostic Regulation to monogenetic disorder testing products, which assigns such tests to a risk-based conformity class, generally requiring notified body assessment and CE marking before a device can be placed on the market, together with a technical file demonstrating analytical and clinical performance. Layered on top of this device framework, Germany's own Genetic Diagnostics Act governs how genetic testing may actually be offered to patients, restricting certain analyses to medical practitioners, mandating pre- and post-test genetic counseling, and setting consent requirements that a supplier's labelling and intended-use documentation must accommodate. Compliance therefore spans both product-level device law and practice-level genetic testing law.
Competition in Germany runs between the suppliers this study tracks: Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings. Two different problems sit on the same axis: holding Diagnostic Testing at 31.98% of 2025 revenue, and taking Prenatal Testing while it grows at 13.93%.
United Kingdom
2nd-largest in Europe, growing 2.3×.
- In region 2 of 3
- Of region 24%
- Of global 6.2%
- Revenue $40.40M → $93.40M
The United Kingdom is sized at USD 40.4 million in 2025, rising to USD 93.4 million by 2034; 6.22% of global revenue and 23.97% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 2.4×.
- In region 3 of 3
- Of region 18%
- Of global 4.7%
- Revenue $30.30M → $73.10M
4.66% of global revenue is generated in France; USD 30.3 million in 2025, reaching USD 73.1 million in 2034, and 17.98% of Europe.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 4.5 points of share by 2034, while revenue still grows 3.1×.
- Rank 3 of 5
- 2025 share 22.5%
- By 2034 27%
- Revenue $146M → $457M
Asia Pacific holds 22.5% of the global monogenetic disorders testing market in 2025, worth USD 146.3 million rising to USD 456.9 million in 2034. Among the five regions it ranks third by revenue in both years.
Its share rises to 27% over the forecast period, so the region grows faster than the market's 11.37% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Segment composition follows the global pattern: Diagnostic Testing largest at 31.98% of 2025 revenue, Prenatal Testing fastest at 13.93%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 3.3×.
- In region 1 of 3
- Of region 34%
- Of global 7.7%
- Revenue $49.70M → $164M
33.97% of Asia Pacific's base-year revenue comes from China; USD 49.7 million, rising to USD 164.4 million by 2034. At 33.97% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 146.3 million in 2025 and USD 456.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The test type pattern in China is the global one: 31.98% of 2025 revenue in Diagnostic Testing, 29.26% by 2034, against 13.93% growth in Prenatal Testing taking it from 24% to 29.58%. Its 33.97% weight in Asia Pacific means those movements carry straight into the regional totals. Per-test type revenue for China appears on its own in the full report.
China regulates monogenetic disorder testing products as in vitro diagnostic devices under the National Medical Products Administration, which classifies devices by risk and generally places genetic testing kits in its higher classification tier, requiring registration review, clinical evaluation data, and conformity with national standards before sale. Because these tests involve human genetic material, suppliers and testing organizations must separately comply with human genetic resources administration rules overseen by the science and technology authorities, which govern the collection, storage, export, and international collaborative use of genetic samples and data. Approval pathways and genetic-resource clearance operate alongside one another, and labelling must reflect the registered intended use and any collaborating institution's authorization status.
In China the field is Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings. Volume sits in Diagnostic Testing at 31.98% of 2025 revenue; movement sits in Prenatal Testing at 13.93% growth.
Japan
2nd-largest in Asia Pacific, growing 2.6×.
- In region 2 of 3
- Of region 24%
- Of global 5.4%
- Revenue $35.10M → $91.40M
Japan is sized at USD 35.1 million in 2025, rising to USD 91.4 million by 2034; 5.4% of global revenue and 23.99% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
India
3rd-largest in Asia Pacific, growing 3.9×.
- In region 3 of 3
- Of region 16%
- Of global 3.6%
- Revenue $23.40M → $91.40M
Within Asia Pacific, India accounts for 15.99% of regional revenue and 3.6% of the global total, worth USD 23.4 million in 2025 and USD 91.4 million by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 0.6 points of share by 2034, while revenue still grows 2.9×.
- Rank 4 of 5
- 2025 share 5.9%
- By 2034 6.5%
- Revenue $38.10M → $110M
5.86% of the global monogenetic disorders testing market sits in Latin America in 2025, worth USD 38.1 million rising to USD 110 million in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 6.5% over the forecast period, at a pace above the 11.37% global rate, which is what makes this region worth reading separately rather than scaling from the total.
Within the region the test type split tracks the global one; 31.98% of 2025 revenue in Diagnostic Testing, fastest growth of 13.93% in Prenatal Testing. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
The largest market in Latin America, growing 2.9×.
- In region 1 of 2
- Of region 55.1%
- Of global 3.2%
- Revenue $21M → $60.50M
55.12% of Latin America's base-year revenue comes from Brazil; USD 21 million, rising to USD 60.5 million by 2034. At 55.12% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 38.1 million and USD 110 million for the region, it is why this market rather than a smaller one is the one reported in full.
Composition here matches the global split: the largest line is Diagnostic Testing at 31.98% of 2025 revenue, easing to 29.26% by 2034, and the fastest is Prenatal Testing at 13.93%, from 24% to 29.58%. Because the country carries 55.12% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Brazil by test type separately.
In Brazil, monogenetic disorder testing products fall under the health surveillance authority, Anvisa, which regulates in vitro diagnostic devices through a risk-based classification system that determines whether a product may be registered through a simplified notification or requires full technical dossier review before it can be marketed. Suppliers must demonstrate conformity with applicable technical standards for performance and safety, maintain Portuguese-language labelling and instructions for use, and hold a valid operating authorization for the establishment placing the product on the market. Laboratories performing the testing are additionally subject to quality and accreditation requirements that apply to clinical diagnostic services more broadly, independent of the device's own registration status.
The suppliers tracked in this study (Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings) compete in Brazil across the test type lines above. Two different problems sit on the same axis: holding Diagnostic Testing at 31.98% of 2025 revenue, and taking Prenatal Testing while it grows at 13.93%.
Mexico
2nd-largest in Latin America, growing 2.9×.
- In region 2 of 2
- Of region 29.9%
- Of global 1.8%
- Revenue $11.40M → $33M
Within Latin America, Mexico accounts for 29.92% of regional revenue and 1.75% of the global total, worth USD 11.4 million in 2025 and USD 33 million by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.6 points of share by 2034, while revenue still grows 3.0×.
- Rank 5 of 5
- 2025 share 3.9%
- By 2034 4.5%
- Revenue $25M → $76.10M
3.86% of the global monogenetic disorders testing market sits in Middle East and Africa in 2025, worth USD 25 million and reaches USD 76.1 million by 2034. Among the five regions it ranks fifth by revenue in both years.
4.5% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 11.37% global rate, which is what makes this region worth reading separately rather than scaling from the total.
Segment composition follows the global pattern: Diagnostic Testing largest at 31.98% of 2025 revenue, Prenatal Testing fastest at 13.93%. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 3.0×.
- In region 1 of 2
- Of region 36%
- Of global 1.4%
- Revenue $9M → $27.40M
36% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 9 million, rising to USD 27.4 million by 2034. Its 36% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. The region itself runs USD 25 million to USD 76.1 million over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Diagnostic Testing at 31.98% of 2025 revenue, easing to 29.26% by 2034, and the fastest is Prenatal Testing at 13.93%, from 24% to 29.58%. Because the country carries 36% of Middle East and Africa, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The full report reports Saudi Arabia by test type separately.
Saudi Arabia regulates monogenetic disorder testing products through the Saudi Food and Drug Authority, which oversees in vitro diagnostic devices under its medical device framework aligned with international harmonization principles. A supplier must obtain marketing authorization by registering the device and its manufacturer in the national medical device registration system, supported by evidence of conformity assessment, before the product can be imported or sold, and the local establishment handling the product typically needs its own licence. Labelling must be presented in Arabic alongside the source language and reflect the authorized intended use, while genetic testing services delivered through healthcare facilities are additionally subject to the health ministry's clinical and laboratory practice requirements.
The suppliers tracked in this study (Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings) compete in Saudi Arabia across the test type lines above. Diagnostic Testing, at 31.98% of 2025 revenue, is where the volume sits, and Prenatal Testing, growing at 13.93%, is where position changes hands over the forecast period.
United Arab Emirates
2nd-largest in Middle East and Africa, growing 3.0×.
- In region 2 of 2
- Of region 28%
- Of global 1.1%
- Revenue $7M → $21.30M
The United Arab Emirates is sized at USD 7 million in 2025, rising to USD 21.3 million by 2034; 1.08% of global revenue and 28% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by test type, disease type, end-user, technology, product & service, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Diagnostic Testing Volume and Prenatal Testing Momentum
The study covers the following suppliers: Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc. and Laboratory Corporation of America Holdings.
The test type axis, not the regional one, is where competition happens. The largest block of revenue is Diagnostic Testing: USD 207.9 million in 2025 at 31.98% of the total, 29.26% in 2034. Incumbency there is expensive to challenge. Prenatal Testing, compounding at 13.93% against 10.32% for New-Born Screening, is where share changes hands over the forecast period. Holding the first and taking the second are separate capabilities, which is why a market of USD 650 million supports as many suppliers as it does.
Suppliers compete primarily on assay breadth and regulatory clearance depth: companies with cleared panels across more of the five test types and disease categories win laboratory contracts that would otherwise require multiple vendors. Manufacturing and reagent supply reliability matter for laboratories running high test volumes, while newer entrants compete on turnaround time and direct engagement with specialized genetic clinics rather than on scale. Distribution reach into hospital and reference laboratory networks favors the larger diagnostics companies, while smaller and regional players compete on faster interpretation reporting and closer clinician relationships in the markets they serve.
The regional picture sets the entry cost: 41.86% of revenue is in North America and 25.93% in Europe, so a credible global position requires both, while Middle East and Africa at 3.86% can be served opportunistically.
The full report carries a profile, financials, share and development history for each company named; none of that is in this summary.
List of Key Monogenetic Disorders Testing Market Companies Profiled
14 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Celera Support Services(United States)
- Abbott(United States)
- ELITech Group(United States)
- Quest Diagnostics Incorporated(United States)
- Auto Genomics(United States)
- PerkinElmer Inc.(United States)
- F. Hoffmann-La Roche Ltd(Switzerland)
- Bio-Rad Laboratories, Inc.(United States)
- Thermo Fisher Scientific, Inc.(United States)
- Illumina, Inc.(United States)
- QIAGEN N.V.(Netherlands)
- Myriad Genetics, Inc.(United States)
- Natera, Inc.(United States)
- Laboratory Corporation of America Holdings(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Test Type, Disease Type, End-user, Technology, Product & Service), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 14 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Monogenetic Disorders Testing Market Size & Projections, 2020–2034, Revenue (USD Million)
Chapter 16.Global Monogenetic Disorders Testing Market Overview, By Test Type, 2020–2034, Revenue (USD Million)
Chapter 17.Global Monogenetic Disorders Testing Market Overview, By Disease Type, 2020–2034, Revenue (USD Million)
Chapter 18.Global Monogenetic Disorders Testing Market Overview, By End-user, 2020–2034, Revenue (USD Million)
Chapter 19.Global Monogenetic Disorders Testing Market Overview, By Technology, 2020–2034, Revenue (USD Million)
Chapter 20.Global Monogenetic Disorders Testing Market Overview, By Product & Service, 2020–2034, Revenue (USD Million)
Chapter 21.Global Monogenetic Disorders Testing Market Size — Segment Comparison
Chapter 22.Global Monogenetic Disorders Testing Geography Overview, 2020–2034, Revenue (USD Million)
Chapter 23.North America Monogenetic Disorders Testing Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 24.Europe Monogenetic Disorders Testing Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 25.Asia Pacific Monogenetic Disorders Testing Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 26.Latin America Monogenetic Disorders Testing Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 27.Middle East and Africa Monogenetic Disorders Testing Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Test Type
5- 01Diagnostic Testing
- 02Prenatal Testing
- 03Carrier Testing
- 04New-Born Screening
- 05Predictive and Pre-Symptomatic Testing
By Disease Type
10- 01Thalassaemia
- 02Sickle Cell Anemia
- 03Cystic fibrosis
- 04Familial Hypercholesterolemia
- 05Huntington's Disease
- 06Severe Combined Immunodeficiency (SCID)
- 07Polycystic Kidney Disorder
- 08Neurofibromatosis
- 09Gaucher's Disease
- 10Tay-Sachs Disorder
By End-user
3- 01Hospitals
- 02Specialized Clinics
- 03Ambulatory Surgical Centers
By Technology
5- 01Next-Generation Sequencing (NGS)
- 02Polymerase Chain Reaction (PCR)
- 03Sanger Sequencing
- 04Microarray
- 05Fluorescence In Situ Hybridization (FISH)
By Product & Service
3- 01Reagents & Consumables
- 02Instruments
- 03Software & Services
Segment categories shown for scope reference. See the Summary tab for revenue share by By Test Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The market was built upward from testing volumes and per-test realized prices for each of the five test types, using national newborn screening program throughput, published carrier and prenatal screening panel counts, and average reimbursed prices for PCR, next-generation sequencing, Sanger sequencing, microarray and FISH platforms. Reagent and instrument revenue was layered on using vendor kit pricing and average testing volumes per instrument placement. The resulting bottom-up figure was checked against disclosed revenue from clinical laboratory and diagnostics companies with named genetic testing lines. Where a country-level bottom-up estimate diverged from the disclosed comparison, the underlying volume or price assumption was corrected rather than averaging the two figures together.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interview targets included laboratory directors and genetic testing product managers who set panel pricing and platform mix, procurement leads at hospital and reference laboratories who select testing vendors, and regulatory affairs contacts who track newborn screening mandate changes by jurisdiction. Reimbursement and payer-policy contacts were also engaged to confirm which test types carry public or private coverage in a given market. Sampling emphasized the United States, Germany, the United Kingdom, China and India, reflecting where newborn screening mandates, reimbursement policy and testing volume are best documented.
Desk research drew on national newborn screening program registries, the U.S. FDA's genetic and molecular test clearance listings, CLIA-certified laboratory directories, published clinical laboratory fee schedules, and customs classifications covering in-vitro diagnostic reagent trade. Company-level context came from annual reports and investor filings of publicly listed diagnostics and laboratory companies named in this report, alongside professional body guidance from clinical genetics societies on recommended testing panels by condition and jurisdiction-level newborn screening panel expansions tracked through public health department bulletins.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from projected newborn screening panel expansion by jurisdiction, the pace at which next-generation sequencing per-test cost continues to fall, and the rate at which carrier and prenatal screening are adopted into standard prenatal care pathways. Reimbursement policy change is modeled by test type rather than applied uniformly, since public coverage for newborn and diagnostic testing is already broad while coverage for predictive and pre-symptomatic testing remains limited in most markets. For the forecast to hold, sequencing cost declines must continue at a pace consistent with the past five years and no major newborn screening mandate may be reversed.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Historical figures were back-tested against recorded newborn screening program enrollment growth and disclosed laboratory revenue growth for 2020 through 2024 before the forecast was built forward. Segment-level shifts, including the growing share of next-generation sequencing relative to Sanger sequencing and microarray platforms, were reviewed against platform adoption reported by testing laboratories. Sensitivities were tested on the pace of reimbursement expansion and on sequencing cost decline, since these two assumptions move the forecast total more than any other input.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmer in newborn screening and diagnostic testing, where program enrollment and reimbursement are publicly documented, and softer in predictive and pre-symptomatic testing, where reporting is thin and uptake depends on individual choice rather than a screening mandate. A reversal or narrowing of a national newborn screening mandate, or a slower than assumed decline in sequencing cost, are the two structural risks most likely to force a revision of this estimate.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Monogenetic Disorders Testing Market projected to reach?
USD 1692.1 Million by 2034, CAGR 11.37%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 41.86% of global revenue through 2034.
05Which segment leads the market?
Diagnostic Testing is the largest line by test type, at 31.98% of revenue in 2025.
06Who are the key companies profiled?
Celera Support Services, Abbott, ELITech Group, Quest Diagnostics Incorporated, Auto Genomics, PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Myriad Genetics, Inc., Natera, Inc., Laboratory Corporation of America Holdings. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.